Bibliografia
1. Imperiale MJ, 2001. The human polyomaviruses: an overview. In: Khalili K, Stoner GL, eds. Human polyomaviruses: Molecular and clinical perspective. New York: Wilsey-Liss Inc: 53-71.
2. Van Regenmortel M, Fauquet C, Bishop D, 2000. Virus Taxonomy. Seventh Report of the International Committee on Taxonomy of Viruses, New York. Arch. Viral. 145:1497-504. 3. Sweet BH, Hilleman MR, 1960. The vacuolating virus, SV40. Proc. Soc. Exp. Biol. Med.
105:420-7.
4. Jackson DA, Symons RH, Berg P, 1972. Biochemical method for inserting new genetic information into DNA of Simian virus 40: circular SV40 DNA molecules containing lambda phage genes and the galactose operon of Escherichia coli. Proc. Natl. Acad. Sci. USA. 69:2904-9.
5. Gardner SD, Field AM, Coleman DV, Hulme B, 1971. New human papovavirus (B.K.) isolated from urine after renal transplantation. Lancet 19:1253-7.
6. Padgett BL, Walker DL, Zu Rhein GM, Eckroade RJ, Dessel BH, 1971. Cultivation of a papova-like virus from human brain with progressive multifocal leukoencephalopathy. Lancet 1:1257-60.
7. Astrom KE, Mancall EL, Richardson EPJr, 1958. Progressive multifocal
leucoencephalopathy. Brain. 81:93-127.
8. Frisque RJ, Bream GL, Cannella MT, 1984. Human polyomavirus JC virus genome. J. Virol. 51:458-69.
9. Allander T, Andreasson K, Gupta S, Bjerkner A, Bogdanovic G, Persson MA, Dalianis T, Ramqvist T, Andersson B, 2007. Identification of a third human polyomavirus. J. Virol. 81:4130-6.
10. Gaynor AM, Nissen MD, Wang D, 2007. Identification of a novel polyomavirus from patients with acute respiratory tract infections. Plos Pathog. 4;3:e64.
11. Feng H, Shuda M , Chang Y, Moore PS, 2008. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 319:1096-100.
12. Johnson EM, 2010. Structural evolution of new human polyomaviruses provides clues to pathobiology. Trends Microbiol. 18:215-23.
13. Johne R, Buck CB, Allander T, Atwood WJ, Garcea RL, Imperiale MJ, Major EO, Ramgvist T, Norkin LC, 2011. Taxonomical developments in the family Polyomaviridae. Arch. Virol. 156:1627-34.
14. Monaco MC, Atwood WJ, Gravell M, Tornatore CS, Major EO, 1996. JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency. J. Virol. 70:7004-12.
15. Berger JR, Major EO, 1999. Progressive multifocal leukoencephalopathy. Semin. Neurol. 19:193-200.
16. Berger JR, Houff S, 2009. Opportunistic infections and other risks with newer multiple sclerosis therapies. Ann. Neurol. 65:367-77.
17. Koralnik IJ, 2004. New insights into progressive multifocal leukoencephalopathy. Curr. Opin. Neurol. 17:365-70.
18. Tan CS, Koralnik IJ, 2010. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol. 9:425-37.
19. Blake K, Pillay D, Knowles W, Brown DW, Griffiths PD, Taylor B, 1992. JC virus associated meningoencephalitis in an immunocompetent girl. Arch. Dis. Child. 67:956-7. 20. Del Valle L, White MK, Khalili K, 2008. Potential mechanisms of the Human
Polyomavirus JCV in Neural oncogenesis. J. Neuropathol. 67:729-40.
21. White MK and Khalili K, 2004. Polyomaviruses and human cancer: molecular mechanisms underlying patterns of tumorigenesis. Virology 324:1-16.
22. Del Valle L, Gordon J, Assimakopoulou M, Enam S, Geddes JF, Varakis JN, Katsetos CD, Khalili K, 2001. Detection of JC virus DNA sequences and expression of the viral regulatory protein T-antigen in tumors of the central nervous system. Cancer Res. 61:4287-93.
23. Caldarelli-Stefano R, Boldorini R, Monga G, Meraviglia E, Zorini EO, Ferrante P, 2000. JC virus in human glial-derived tumors. Hum. Pathol. 31:394-5.
24. Del Valle L, Gordon J, Enam S, Delbue S, Croul S, Abraham S, Radhakrishnan S, Assimakopoulou M, Katsetos CD, Khalili K, 2002. Expression of human neurotropic polyomavirus JCV late gene product agnoprotein in human medulloblastoma. J. Natl. Cancer Inst. 94:267-73.
25. Del Valle L, Delbue S, Gordon J, Enam S, Croul S, Ferrante P, Khalili K, 2002. Expression of JC virus T-antigen in a patient with MS and glioblastoma multiforme. Neurology 58:895-900.
26. Lin PY, Fung CY, Chang FP, Huang WS, Chen WC, Wang JY, Chang D, 2008. Prevalence and genotype identification of human JC virus in colon cancer in Tawain. J. Med. Virol. 80:1828-34.
27. Laghi L, Randolph AE, Chauhan DP Marra G, Major EO, Neel JV, Boland CR, 1999. JC virus DNA is present in the mucosa of the human colon and in colonrectal cancers. Proc. Natl. Acad. Sci. USA. 96:7484-9.
28. Del Valle L, White MK, Enam S, Piña Oviedo S, Bromer MQ, Thomas RM, Parkman HP, Khalili K, 2005. Detection of JC virus DNA sequences and expression of viral T antigen and agnoprotein in esophageal cancinoma. Cancer 103:516-27.
29. Murai Y, Zheng HC, Abdel Aziz HO, Mei H, Kutsuna T, Nakanishi Y, Tsuneyama K, Takano Y, 2007. High JC virus load in gastric cancer and adjacent non-cancerous mucosa. Cancer Sci. 98:25-31.
30. Shin SK, Li MS, Fuerst F, Hotchkiss E, Meyer R, Kim IT, Goel A, Boland CR, 2006. Oncogenic T-antigen of JC virus is present frequently in human gastric cancers. Cancer 107:481-8.
31. Zheng H, Abdel Aziz HO, Nakanishi Y, Masuda S, Saito H, Tsuneyama K, Takano Y, 2007. Oncogenic role of JC virus in lung cancer. J. Pathol. 212:306-15.
32. White MK, Gordon J, Reiss K, del Valle L, Croul S, Giordano A, Darbinyan A, Khalili K, 2005. Human polyomaviruses and brain tumors. Brain Res. Rev. 50:69-85.
33. Maginnis MS and Atwood WJ, 2009. JC virus: An oncogenic virus in animals and humans? Semin. Cancer Biol.19:261-9.
34. Bolen JB, Anders DO, Trempy J, Consigli RA, 1981. Differences in the subpopulations of the structural proteins of polyoma virions and capsidis: biological functions of the multiple VP1 species. J. Virol. 37:80-90.
35. Atwood WJ, 2001. Cellular receptors for the polyomaviruses. In: Khalili K, Stoner GL, eds. Human polyomaviruses: Molecular and clinical perspective. New York: Wilsey-Liss Inc: 53-71.
36. Sugimoto C, Hasegawa M, Kato A, Zheng HY, Ebihara H, Taguchi F, Kitamura T, Yogo Y, 2002. Evolution of human Polyomavirus JC: implications for the population history of humans. J. Mol. Evol. 54:285-97.
37. Sugimoto C, Hasegawa M, Kato A, Zheng HY, Ebihara H, Taguchi F, Kitamura T, Yogo Y, 2004. JC virus genotyping offers a new paradigm in the study of human populations. Rev. Med. Virol. 14:179-91.
38. Jobes DV, Friedlaender JS, Mgone CS, Agostini HT, Koki G, Yanagihara R, Ng TCN, Chima SC, Ryschkewitsch CF, Stoner GL, 2001. New JC virus (JCV) genotypes from Papua New Guinea and Micronesia (Type 8 and type 2E) and evolutionary analysis of 32 complete JCV genomes. Arch. Virol. 146:2097-113.
39. Agostini HT, Ryschkewitsch CF, Brubaker GR, Shao J, Stoner GI, 1997. Five complete genomes of JC virus type 3 from Africans and African Americans. Arch. Virol. 142:637-55. 40. Agostini HT, Ryschkewitsch CF, Stoner GL, 1996. Genotype profile of human
polyomavirus JC excreted in urine of immunocompetent individuals. J. Clin. Microbiol. 34:159-64.
41. Iacoangeli A, Melucci-Vigo G, Risuleo, Santi E, 1995. Role of mouse polyomavirus late region in the control of viral DNA replication: a review. Biochimie. 77:780-6.
42. ChenYH, MacGregor JP, Goldstein DA, Hall MR, 1979. Histone modifications in simian virus 40 and in nucleoprotein complexes containing supercoiled viral DNA. J. Virol. 30:218-24.
43. Tan KB, 1977. Histones: metabolism in simian virus 40-infected cells and incorporation into virions. Proc. Natl. Acad. Sci. USA 74:2805-09.
44. Eash S, Manley K, Gasparovic W, Querbes W, Atwood WJ, 2006. The human polyomaviruses. Cell Mol. Life Sci. 63:865-76.
45. Jensen PN, Major EO, 2001. A classification scheme for human polyomavirus JCV variants based on the nucleotide sequence of the noncoding regulatory region. J. Neurovirol. 7:280-7.
46. Berger JR, 2007. Progressive multifocal leukoencephalopathy. Curr. Neurol. Neurosci Rep. 7:461-9.
47. Trowbridge PW, Frisque RJ, 1995. Identification of three new JC virus proteins generated by alternative splicing of the early viral mRNA. J. Neurovirol. 1:195-206.
48. Major EO, Amemiya K, Tornatore CS, Houff SA, Berger JR, 1992. Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin. Microbiol. Rev. 5:49-73.
49. Cress WD, Nevins JR, 1996. Use of the E2F transcription factor by DNA tumor virus regulatory proteins. Curr. Top. Microbiol. Immunol. 208:63-78.
50. Krynska B, Gordon J, Otte J, Franks R, Knobler R, DeLuca A, Giordano A, Khalili K, 1997. Role of cell cycle regulators in tumor formation in transgenic mice expressing the human neurotropic virus, JCV, early protein. J. Cell. Biochem. 67:223-30.
51. Tavis JE, Trowbridge PW, Frisque RJ, 1994. Converting the JCV T antigen Rb binding domain to that of SV40 does not alter JCV's limited transforming activity but does eliminate viral viability. Virology 199:384-92.
52. Bollag B, Chuke WF, Frisque RJ, 1989. Hybrid genomes of the polyomaviruses JC virus, BK virus, and simian virus 40: Identification of sequences important for efficient transformation. J. Virol. 63:863-72.
53. Lassak A, Del Valle L, Peruzzi F, Wang JY, Enam S, Croul S, Khalili K, Reiss K, 2002. Insulin receptor substrate translocation to the nucleus by the human JC virus T-antigen. J. Biol. Chem. 277:17231-8.
54. Enam S, Del Valle L, Lara C, Gan DD, Ortiz-Hidalgo C, Palazzo JP, Khalili K, 2002. Association of human polyomavirus JCV with colon cancer: Evidence for interaction of viral T-antigen and beta-catenin. Cancer Res. 62:7093-101.
55. Gan DD, Khalili K., 2004. Interaction between JCV large T-antigen and beta-catenin. Oncogene 23:483-90.
56. Shollar D, Del Valle L, Khalili K, Otte J, Gordon J, 2004. JCV T-antigen interacts with the neurofibromatosis type 2 gene product in a transgenic mouse model of malignant peripheral nerve sheath tumors. Oncogene 23:5459-67.
57. Ahsan N, Shan KV, 2006. Polyomaviruses and human diseases. Adv. Exp. Med. Biol. 577:1-18.
58. Endo S, Okada Y, Orba Y, Nishihara H, Tanaka S, Nagashima K, Sawa H, 2003. JC virus agnoprotein colocalizes with tubulin. J. Neurovirol. 1:10-4.
59. Suzuki T, Orba Y, Okada Y, Sunden Y, Kimura T, Tanaka S, Nagashima K, Hall WW, Sawa H, 2010. The human polyoma JC virus agnoprotein acts as a viroporin. PLoS Pathog. 6:e1000801.
60. Khalili K, Rappaport J, Khoury G, 1988. Nuclear factors in human brain cells bind specifically to the JCV regulatory region. EMBO J. 7:1205-10.
61. White MK, Safak M and Khalili K, 2009. Regulation of gene expression in Primate Polyomaviruses. J. Virol. 83:10846-56.
62. Agostini HT, Ryschkewitsch CF, Singer EJ, Stoner GL, 1997. JC virus regulatory region rearrangements and genotypes in progressive multifocal leukoencephalopathy: two independent aspects of virus variation. J. Gen. Virol. 78:659-64.
63. Boldorini R, Allegroni S, Miglio U, Paganotti A, Cocca N, Zaffarono M, Riboni F, Monga G, Viscidi R, 2011. Serological evidence of vertical transmission of JC and BK polyomaviruses in humans. J. Gen. Virol. 92:1044-50.
64. Stolt A, Sasnauskas K, Koskeda P, Lehtinen M, Dillner J, 2003. Seroepidemiology of the human polyomaviruses. J. Gen. Virol. 84:1499-504.
65. Walker D, Padgett B, 1983. The epidemiology of human polyomaviruses. In: Sever J, Madden D, eds. Polyomaviruses and the human neurological disease. New York: Alan R Liss.105:99-106.
66. Egli A, Infanti L, Dumoulin A, Buser A, Samaridis J, Stebler C, Gosert R, Hirsch HH, 2009. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J. Infect. Dis. 199:837-46.
67. Coleman D, Wolfendale M, Daniel R, Dhanial NK, Gardener SD, Gibson PE, Field AM, 1980. A prospective study of human polyomavirus infection in pregnancy. J. Infect. Dis. 142:1-8.
68. Elphick GF, Querbes W, Jordan JA, Gee GV, Eash S, Manley K, Dugan A, Stanifer M, Bhatnagar A, Kroeze WK, Roth BL, Atwood WJ, 2004. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 306:1380-3.
69. Caldarelli-Stefano R, Vago L, Omodeo-Zorini E, Mediati M, Losciale L, Nebuloni M, Costanzi G, Ferrante P, 1999. Detection and typing of JC virus in autopsy brains and extraneural organs of AIDS patients and non-immunocompromised individuals. J. Neurovirol. 5:125-33.
70. Grinnell BW, Padgett BL, Walker DL, 1983. Distribution of nonintegrated DNA from JC papovavirus in organs of patients with progressive multifocal leukoencephalopathy. J. Infect. Dis. 147:669–75.
71. Seth P, Diaz F, Major EO, 2003. Advances in the biology of JC virus and induction of progressive multifocal leukoencephalopathy. J. Neurovirol. 9:236-46.
72. Ferrante P, Caldarelli-Stefano R, Omodeo-Zorini E, Vago L, Boldorini R, Costanzi G, 1995. PCR detection of JC virus DNA in brain tissue from patients with and without progressive multifocal leukoencephalopathy. J. Med. Virol. 47:219-25.
73. Perez-Liz G, Del Valle L, Gentilella A, Croul S, Khalili K, 2008. Detection of JC virus DNA fragments but not proteins in normal brain tissue. Ann. Neurol. 64:379-87.
74. Monaco MC, Jensen PN, Hou J, Durham LC, Major EO, 1998. Detection of JC virus DNA in human tonsil tissue: evidence for site of initial infection. J. Virol. 72:9918-23.
75. Kato A, Kitamura T, Takasaka T, Tominaga T, Ishikawa A, Zheng HY, Yogo Y, 2004. Detection of archetypal regulatory region of JC virus from the tonsil tissue of patients with tonsillitis and tonsillar hypertrophy. J. Neurovirol. 10:244-9.
76. Ricciardiello L, Laghi L, Ramamirtham P, Chang CL, Chang DK, Randolph AE, Boland CR, 2000. JC virus DNA sequences are frequently present in human upper and lower gastrointestinal tract. Gastroenterology 119:1228-35.
77. Ricciardiello L, Chang DK, Laghi L, Goel A, Chang CL, Boland CR, 2001 Mad-1 is exclusive JC virus strain present in the human colon, and its transcriptional control region has a deleted 98-base-pair sequence in colon cancer tissue. J. Virol. 75:1996-2001.
78. White MK and Khalili K, 2011. Pathogenesis of Progressive Multifocal
Leukoencephalopathy-Revisited. J. Infect. Dis. 203:578-86.
79. Berger JR, Miller CS, Mootoor Y, Avdiushko SA, Kryscio RJ, Zhu H, 2006. JC virus detection in bodily fluids: clues to transmission. Clin. Infect. Dis. 43:9-12.
80. Bofill-Mas S, Formiga-Cruz M, Clemente-Casares P, Calafell F, Girones R, 2001. Potential transmission of human polyomaviruses through the gastrointestinal tract after exposure to virions or viral DNA. J. Virol. 75:10290-9.
81. Chesters PM, Heritage J, McCance DJ, 1983. Persistence of DNA sequences of BK virus and JC virus in normal human tissues and in diseased tissues. J. Infect. Dis. 147:676-84. 82. Houff SA, Berger JR, 2008. The bone marrow, B cells, and JC virus. J. Neurovirol.
14:341-3.
83. Marzocchetti A, Wuthrich C, Tan CS, Tompkins T, Bernal-Cano F, Bhargava P, Ropper AH, Koralnik IJ, 2008. Rearrangement of the JC virus regulatory region sequence in the bone marrow of a patient with rheumatoid arthritis and progressive multifocal leukoencephalopathy. J. Neurovirol. 14:455-8.
84. Azzi A, De Santis R, Ciappi S , Leoncini F, Sterrantino G, Marino N, Mazzotta F, Laszlo D, Fanci R, Bosi A, 1996. Human polyomaviruses DNA detection in peripheral blood leukocytes from immunocompetent and immunocompromised individuals. J. Neurovirol. 2:411-6.
85. Houff SA, Major EO, Katz DA, Kufta CV, Sever JL, Pittaluga S, Roberts JR, Gitt J, Saini N, Lux W, 1988. Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. N. Engl. J. Med. 318:301-5.
86. Tan C, Dezube B, Bhargava P, Autissier P, Wüthrich C, Miller J, Koralnik IJ, 2009. Detection of JC virus DNA and proteins in the bone marrow of positive and HIV-negative patients: implications for viral latency and neurotropic transformation. J. Infect. Dis. 199:881-8.
87. Major EO, 2010. Progressive Multifocal Leukoencephalopathy in patients on immunomodulatory therapies. Annu. Rev. Med. 61:35-47.
88. Zu Rhein GM, 1967. Polyoma-like virions in a human demyelinating disease. Acta Neuropathol. 8:57-68.
89. Johnson RT, 1982. Viruses and chronic neurological diseases. Johns Hopkins Med. J. 150:132-40.
90. Power C, Gladden JG, Halliday W, Del Bigio MR, Nath A, Ni W, Major EO, Blanchard J, Mowat M, 2000. AIDS- and non-AIDS-related PML association with distinct p53 polymorphism. Neurology 54:743-6.
91. Gonzalez H, Bolgert F, Camporo P, Leblond V, 1999. Progressive multifocal leukoencephalitis (PML) in three patients treated with standard-dose fludarabine (FAMP). Hematol. Cell. Ther. 41:183-6.
92. Brooks BR, Walker DL, 1984. Progressive multifocal leukoencephalopathy. Neurol. Clin. 2:299-313.
93. Holman RC, Torok TJ, Belay ED, Janssen RS, Schonberger LB, 1998. Progressive multifocal leukoencephalopathy in the United States, 1979-1994: increased mortality associated with HIV infection. Neuroepidemiology 17:303-9.
94. Engsig FN, Hansen AB, Omland LH, Kronborg G, Gerstoft J, Laursen AL, Pedersen C, Mogensen CB, Nielsen L, Obel N, 2009. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J. Infect. Dis. 199:77-83. 95. Berenguer J, Miralles P, Arrizabalaga J, Ribera E, Dronda F, Baraia-Etxaburu J, Domingo
P, Márquez M, Rodriguez-Arrondo FJ, Laguna F, Rubio R, Lacruz Rodrigo J, Mallolas J,
de Miguel V; GESIDA 11/99 Study Group, 2003. Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. Clin. Infect. Dis. 36:1047-52.
96. Lima MA, Bernal-Cano F, Clifford BD, Gandhi RT, Koralnik IJ, 2010. Clinical outcome of long-term survivors of progressive multifocal leukoencephalopathy J. Neurol. Neurosurg. Psychiatry 81:1288-91.
97. Sacktor N, 2002. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J. Neurovirol. 2:115-21.
98. Berger JR, Chauhan A, Galey D, Nath A, 2001. Epidemiological evidence and molecular basis of interactions between HIV and JC virus. J. Neurovirol. 7:329-38.
99. Berger JR, Houff SA and Major EO, 2009. Monoclonal antibodies and progressive multifolcal leukoecephalopathy. MAbs 1:583-9.
100. Berger JR, 2010. Progressive multifocal leukoencephalopathy and newer biological agents. Drug Saf. 1:969-83.
101. Kappos L, Bates D, Edan G, Eraksoy M, Garcia-Merino A, Grigoriadis N, Hartung HP, Havrdová E, Hillert J, Hohlfeld R, Kremenchutzky M, Lyon-Caen O, Miller A, Pozzilli C, Ravnborg M, Saida T, Sindic C, Vass K, Clifford DB, Hauser S, Major EO, O'Connor PW, Weiner HL, Clanet M, Gold R, Hirsch HH, Radü EW, Sørensen PS, King J, 2011. Natatlizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol. 10:745-58.
102. Berger JR, 2011. The basis for modelling progressive multifocal leukoencephalopathy pathogenesis. Curr. Opin. Neurol. 24:262-7.
103. White FA, Ishaq M, Stoner GL, Frisque RJ, 1992. JC virus DNA is present in many human brain samples from patients without progressive multifocal leukoencephalopathy. J. Virol. 66:5726-34.
104. Dorries K, 2006. Human polyomavirus JC and BK persistent infection. Adv. Exp. Med. Biol. 577:102-16.
105. Weber T, Weber F, Petry H, Luke W, 2001. Immune response in progressive multifocal leukoencephalopathy: an overview. J. Neurovirol. 7:311-7.
106. Berger JR, Scott G, Albrecht J, Belman AL, Tornatore C, Major EO, 1992. Progressive multifocal leukoencephalopathy in HIV-1-infected children. AIDS 6:837-41.
107. Tavazzi E, White MK and Khalili K, 2011. Progressive multifocal leukoencephalopathy: clinical and molecular aspects. Rev. Med. Virol. 10.1002/rmv.710.
108. Lam WY, Leung BW, Chu IM, Chan AC, Ng HK, Chan PK, 2010. Survey for the presence of BK, JC, KI, WU and Merkel cell polyomaviruses in human brain tissues. J. Clin. Virol. 48:11-4.
109. Tan CS, Ellis LC, Wüthrich C, Ngo L, Broge TAJr, Saint-Aubyn J, Miller JS, Koralnik IJ, 2010. JC virus latency in the brain and extraneuralorgans of patients with and without progressive multifocal leukoencephalopathy. J. Virol. 84:9200-09.
110. Weber F, Goldmann C, Krämer M, Kaup FJ, Pickhardt M, Young P, Petry H, Weber T,
Lüke W, 2001. Cellular and humoral immune response in progressive multifocal
leukoencephalopathy. Ann. Neurol. 49:636-42.
111. Kedar S, Berger JR, 2011. The changing landscape of progressive multifocal leukopencephalopathy. Curr. Infect. Dis. Rep. 13:380-6.
112. Travis J, Varma A, duPlessis D, Turnbull I, Vilar FJ, 2008. Immune reconstitution associated with progressive multifocal leukoencephalopathy in human immunodeficiency virus: a case discussion and review of the literature. Neurologist 14:321-6.
113. Du Pasquier RA, Kuroda MJ, Zheng Y, Jean-Jacques J, Letvin NL, Koralnik IJ, 2004. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain 127:1970-8.
114. Koralnik IJ, Du Pasquier RA, Kuroda MJ, Schmitz JE, Dang X, Zheng Y, Lifton M, Letvin NL, 2002. Association of prolonged survival in HLA-A2+ progressive multifocal leukoencephalopathy patients with a CTL response specific for a commonly recognized JC virus epitope. J. Immunol. 168:499-504.
115. Koralnik IJ, 2002. Overview of the cellular immunity against JC virus in progressive multifocal leukoencephalopathy. J. Neurovirol. 2:59-65.
116. Koralnik IJ, 2006 Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name? Ann. Neurol. 60:162-73.
117. Marshall LJ, Major EO, 2010. Molecular regulation of JC virus tropism: insights into potential therapeutic targets for progressive multifocal leukoencephalopathy. J. Neuroimmune Pharmacol. 5:404-17.
118. Amemiya K, Traub R, Durham L, Major EO, 1992. Adjacent nuclear factor-1 and activator protein binding sites in the enhancer of the neurotropic JC virus. A common characteristic of many brain-specific genes. J. Biol. Chem. 267:14204-11.
119. Marshall LJ, Dunham L, Major EO, 2010. Transcription factor Spi-B binds unique sequences present in the tandem repeat promoter/enhancer of JC virus and supports viral
120. Kumar KU, Pater A, Pater MM, 1993. Human JC virus perfect palindromic nuclear factor 1-binding sequences important for glial cell-specific expression in differentiating embryonal carcinoma cells. J. Virol. 67:572-6.
121. Sock E, Wegner M, Grummt F, 1991. DNA replication of human polyomavirus JC is stimulated by NF-I in vivo. Virology 182:298-308.
122. Ranganathan PN, Khalili K, 1993. The transcriptional enhancer element, kappa B, regulates promoter activity of the human neurotropic virus, JCV, in cells derived from the CNS. Nucleic Acids Res. 21:1959-64.
123. Raj GV, Khalili K, 1995. Transcriptional regulation: lessons from the human neurotropic polyomavirus, JCV. Virology 213:283-91.
124. Mayreddy RP, Safak M, Razmara M, Zoltick P, Khalili K, 1996. Transcription of the JC virus archetype late genome: importance of the kappa B and the 23-base-pair motifs in late promoter activity in glial cells. J. Virol. 70:2387-93.
125. Safak M, Gallia GL, Khalili K, 1999. A 23-bp sequence element from human neurotropic JC virus is responsive to NF-kappa B subunits. Virology 262:178-89.
126. Romagnoli L, Wollebo HS, Deshmane SL, Mukerjee R, Del Valle L, Safak M, Khalili K, White MK, 2009. Modulation of JC virus transcription by C/EBPbeta. Virus Res. 146:97-106.
127. Gosert R, Kardas P, Major EO, Hirsch HH, 2010. Rearranged JC virus noncoding control regions found in progressive multifocal leukoencephalopathy patient samples increase virus early gene expression and replication rate. J. Virol. 84:10448-56.
128. Daniel AM, Swenson JJ, Mayreddy RP, Khalili K, Frisque RJ, 1996. Sequences within the early and late promoters of archetype JC virus restrict viral DNA replication and infectivity. Virology 216:90-101.
129. Zheng HY, Ikegaya H, Takasaka T, Matsushima-Ohno T, Sakurai M, Kanazawa I, Kishida S, Nagashima K, Kitamura T, Yogo Y, 2005. Characterization of the VP1 loop mutations widespread among JC polyomavirus isolates associated with progressive multifocal leukoencephalopathy. Biochem. Biophys. Res. Comm. 333:996-1002.
130. Delbue S, Branchetti E, Bertolacci S, Tavazzi E, Marchioni E, Maserati R, Minnucci G, Tremolada S, Vago G, Ferrante , 2009. JC virus VP1 loop-specific polymorphisms are associated with favorable prognosis for progressive multifocal leukoencephalopathy. J. Neurovirol. 15:51-6.
131. Sunyaev SR, Lugovskoy A, Simon K, Gorelik L, 2009. Adaptive mutations in the JC virus protein capsid are associated with progressive multifocal leukoencephalopathy (PML). PLoS Genet. 5:e1000368.
132. Gorelik L, Reid C, Testa M, Brickelmaier M, Bossolasco S, Pazzi A, Bestetti A, Carmillo P, Wilson E, McAuliffe M, Tonkin C, Carulli JP, Lugovskoy A, Lazzarin A, Sunyaev S, Simon K, Cinque P, 2011. Progressive multifocal leukoencephalopathy (PML) development is associated with mutations in JC virus capsid protein VP1 that change its receptor specificity. J. Infect. Dis. 204:103-14.
133. Akan I, Sariyer IK, Biffi R, Palermo V, Woolridge S, White MK, Amini S, Khalili K, Safak M, 2006. Human polyomavirus JCV late leader peptide region contains important regulatory elements. Virology 349:66-78.
134. Ghosh Z, Mallick B, Chakrabarti J, 2009. Cellular versus viral microRNAs in host-virus interaction. Nucleic Acids Res. 37:1035-48.
135. Sullivan CS, Grundhoff A, 2007. Identification of viral microRNAs. Methods Enzymol. 427:3-23.
136. Seo GJ, Fink LH, O'Hara B, Atwood WJ, Sullivan CS, 2008. Evolutionarily conserved function of a viral microRNA. J Virol. 82:9823-8.
137. Chan AC, Carter PJ, 2010. Therapeutic antibodies for autoimmunity and inflammation. Nat. Rev. Immunol. 10:301-16.
138. Presta LG, 2006. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv. Drug Deliv. Rev. 58:640-56.
139. Focosi D, Maggi F, Pistello M, Boggi U, Scatena F, 2011. Immunosuppressive monoclonal antibodies: current and next generation. Clin. Microbiol. Infect. 17:1759-68.
140. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N, 1992. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 356:63-6.
141. Cannella B, Raine CS, 1995. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann. Neurol. 37:424-35.
142. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators, 2006. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N. Engl. J. Med. 354:911-23.
143. Lee SJ, Benveniste EN, 1999. Adhesion molecule expression and regulation on cells of the central nervous system. J. Neuroimmunol. 98:77-88.
144. Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J, Curfman B, Miszkiel K, Mueller-Lenke N, Sanchez E, Barkhof F, Radue EW, Jäger HR, Clifford DB, 2006. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med. 354:924-33.
145. EMEA European Medicines Agency. Tysabri. European Public Assessment Report (EPAR). http://www.ema.europa.eu/humandocs/Humans/EPAR/tysabri/tysabri.htm . 18-6-2009 (ultimo accesso il 30.12.2011).
146. Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A, 2010. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 9:438-46.
147. Gürcan HM, Keskin DB, Stern JN, Nitzberg MA, Shekhani H, Ahmed AR, 2009. A review of the current use of rituximab in autoimmune diseases. Int. Immunopharmacol. 9:10-25. 148. Johnson P, Glennie M, 2003. The mechanisms of action of rituximab in the elimination of
tumor cells. Semin. Oncol. 30:3-8.
149. Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP, Bennett CL, 2009. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on
150. Gever J, 2009. Third PML case reported with rituximab. Med-Page Today2009(online). Available from URL:http://www.medpagetoday.com/Product alert/Prescriptions/16607. (ultimo accesso il 30.12.2011).
151. Leonardi CL, 2004. Current concepts and review of efalizumab in the treatment of psoriasis. Dermatol. Clin. 22:427-35.
152. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, Bresnahan BW, Menter A; Efalizumab Study Group, 2003. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 290:3073-80.
153. Bressler B, Haraoui B, Keystone EC, Sette A, 2010. Optimizing use of tumor necrosis factor inhibitors in the management of immune-mediated inflammatory diseases. J. Rheumatol. 37:40-52.
154. Silva LC, Ortigosa LC, Benard G, 2010. Anti-TNF-á agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy 2:817-33.
155. Kumar D, Bouldin TW, Berger RG, 2010. A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab. Arthritis Rheum. 62:3191-5. 156. Maggi F, Andreoli E, Lanini L, Fornai C, Vatteroni M, Pistello M, Presciuttini S,
Bendinelli M, 2005. Relationships between total plasma load of torquetenovirus (TTV) and TTV genogroups carried. J. Clin. Microbiol. 43:4807-10.
157. Chen Y, Bord E, Tompkins T, Miller J, Tan CS, Kinkel RP, Stein MC, Viscidi RP, Ngo LH, Koralnik IJ, 2009. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N. Engl. J. Med. 361:1067-74
158. Maggi F, Bendinelli M, 2009. Immunobiology of the Torquetenoviruses and other anelloviruses. Curr. Top Microbiol. Immunol. 331:65-90.
159. Gergely PJr, Perl A, Poor G, 2006. Possible pathogenic nature of the recently discovered TT virus: does it play a role in autoimmune rheumatic diseases? Autoimmun Rev. 6:5-9. 160. Focosi D, Maggi F, Andreoli E, Lanini L, Ceccherini-Nelli L, Petrini M , 2009. The role of
bone marrow cells for JCV pathogenicity. J. Clin. Virol. 45:230-1.
161. Zhong S, Yeo W, Tang M, Liu C, Lin XR, Ho WM, Hui P, Johnson PJ, 2002. Frequent detection of the replicative form of TT virus DNA in peripheral blood mononuclear cells and bone marrow cells in cancer patients. J. Med. Virol. 66:428-34.
162. Focosi D, Maggi F, Albani M, Macera L, Ricci V, Gragnani S, Di Beo S, Ghimenti M, Antonelli G, Bendinelli M, Pistello M, Ceccherini-Nelli L, Petrini M, 2010. Torquetenovirus viremia kinetics after autologous stem cell transplantation are predictable and may serve as a surrogate marker of functional immune reconstitution. J. Clin. Virol. 47:189-92.
